• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

更正：银屑病关节炎患者中4年期间使用与不使用改善病情抗风湿药的赛妥珠单抗聚乙二醇化制剂的疗效：RAPID-PsA随机对照试验结果。

Correction to: Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial.

作者信息

Walsh J A, Gottlieb A B, Hoepken B, Nurminen T, Mease P J

机构信息

Division of Rheumatology, University of Utah School of Medicine, Salt Lake City, UT, USA.

Department of Dermatology, New York Medical College, Metropolitan Hospital, New York, NY, USA.

出版信息

Clin Rheumatol. 2018 Dec;37(12):3297. doi: 10.1007/s10067-018-4311-z.

DOI:10.1007/s10067-018-4311-z
PMID:30311014
Abstract

The above article originally published with an error present in Discussion section and presented correctly in this article. The original article was corrected.

摘要

上述文章最初发表时在讨论部分存在错误，本文已正确呈现。原始文章已得到修正。

相似文献

1
Correction to: Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial.更正：银屑病关节炎患者中4年期间使用与不使用改善病情抗风湿药的赛妥珠单抗聚乙二醇化制剂的疗效：RAPID-PsA随机对照试验结果。
Clin Rheumatol. 2018 Dec;37(12):3297. doi: 10.1007/s10067-018-4311-z.
2
Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial.在银屑病关节炎患者中，培戈洛单抗联合或不联合疾病修正抗风湿药物治疗 4 年的疗效：来自 RAPID-PsA 随机对照试验的结果。
Clin Rheumatol. 2018 Dec;37(12):3285-3296. doi: 10.1007/s10067-018-4227-7. Epub 2018 Sep 6.
3
Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.聚乙二醇化赛妥珠单抗（CDP870）用于治疗成人类风湿性关节炎。
Cochrane Database Syst Rev. 2014 Sep 18(9):CD007649. doi: 10.1002/14651858.CD007649.pub3.
4
Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.聚乙二醇化赛妥珠单抗（CDP870）用于治疗成人类风湿性关节炎。
Cochrane Database Syst Rev. 2017 Sep 8;9(9):CD007649. doi: 10.1002/14651858.CD007649.pub4.
5
Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection.肿瘤坏死因子-α抑制剂治疗银屑病关节炎合并丙型肝炎病毒感染领域的当前证据。
Expert Opin Biol Ther. 2015 May;15(5):641-50. doi: 10.1517/14712598.2015.1011616. Epub 2015 Feb 4.
6
Certolizumab pegol: in rheumatoid arthritis.注射用培塞利珠单抗：治疗类风湿关节炎。
BioDrugs. 2009;23(6):407-17. doi: 10.2165/11202800-000000000-00000.
7
Correction: .更正：.
RMD Open. 2018 Mar 26;4(1). doi: 10.1136/rmdopen-2017-000582corr1. eCollection 2018.
8
New Approaches in Tumor Necrosis Factor Antagonism for the Treatment of Psoriatic Arthritis: Certolizumab Pegol.肿瘤坏死因子拮抗剂治疗银屑病关节炎的新方法：聚乙二醇化赛妥珠单抗
J Rheumatol Suppl. 2015 Nov;93:70-2. doi: 10.3899/jrheum.150641.
9
Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.培塞丽珠单抗和司库奇尤单抗治疗改善病情抗风湿药物治疗应答不足的活动性银屑病关节炎：系统评价和经济评价。
Health Technol Assess. 2017 Oct;21(56):1-326. doi: 10.3310/hta21560.
10
Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.聚乙二醇化赛妥珠单抗（CDP870）用于成人类风湿关节炎的治疗。
Cochrane Database Syst Rev. 2011 Feb 16(2):CD007649. doi: 10.1002/14651858.CD007649.pub2.

引用本文的文献

1
Tumor necrosis factor (TNF) inhibitors for psoriatic arthritis.用于治疗银屑病关节炎的肿瘤坏死因子（TNF）抑制剂。
Cochrane Database Syst Rev. 2025 Feb 13;2(2):CD013614. doi: 10.1002/14651858.CD013614.pub2.